Stock Track | Adaptive Biotechnologies Soars 5.52% Pre-market on Strong Q2 Results and Upgraded Price Target

Stock Track2025-08-06

Adaptive Biotechnologies Corp (ADPT) saw its stock surge 5.52% in pre-market trading on Wednesday, following the release of better-than-expected second-quarter results and an analyst upgrade.

The company reported a narrower loss of $0.17 per diluted share for Q2, compared to a loss of $0.31 a year earlier and beating analyst expectations of a $0.25 loss. Revenue for the quarter ended June 30 jumped to $58.9 million, significantly higher than the $43.2 million reported in the same period last year and surpassing the FactSet analyst consensus of $49.4 million.

Adding to the positive sentiment, JP Morgan raised its price target for Adaptive Biotechnologies from $10 to $14, reflecting increased confidence in the company's future performance. The combination of strong financial results and the upgraded analyst outlook appears to be driving investor enthusiasm, resulting in the notable pre-market price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183509733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183509733","market":"nz","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 5.52% Pre-market on Strong Q2 Results and Upgraded Price Target","media":"Stock Track","content":"<p>Adaptive Biotechnologies Corp (ADPT) saw its stock surge 5.52% in pre-market trading on Wednesday, following the release of better-than-expected second-quarter results and an analyst upgrade.</p>\n\n<p>The company reported a narrower loss of $0.17 per diluted share for Q2, compared to a loss of $0.31 a year earlier and beating analyst expectations of a $0.25 loss. Revenue for the quarter ended June 30 jumped to $58.9 million, significantly higher than the $43.2 million reported in the same period last year and surpassing the FactSet analyst consensus of $49.4 million.</p>\n\n<p>Adding to the positive sentiment, JP Morgan raised its price target for Adaptive Biotechnologies from $10 to $14, reflecting increased confidence in the company's future performance. The combination of strong financial results and the upgraded analyst outlook appears to be driving investor enthusiasm, resulting in the notable pre-market price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 5.52% Pre-market on Strong Q2 Results and Upgraded Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 5.52% Pre-market on Strong Q2 Results and Upgraded Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Adaptive Biotechnologies Corp (ADPT) saw its stock surge 5.52% in pre-market trading on Wednesday, following the release of better-than-expected second-quarter results and an analyst upgrade.</p>\n\n<p>The company reported a narrower loss of $0.17 per diluted share for Q2, compared to a loss of $0.31 a year earlier and beating analyst expectations of a $0.25 loss. Revenue for the quarter ended June 30 jumped to $58.9 million, significantly higher than the $43.2 million reported in the same period last year and surpassing the FactSet analyst consensus of $49.4 million.</p>\n\n<p>Adding to the positive sentiment, JP Morgan raised its price target for Adaptive Biotechnologies from $10 to $14, reflecting increased confidence in the company's future performance. The combination of strong financial results and the upgraded analyst outlook appears to be driving investor enthusiasm, resulting in the notable pre-market price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1183509733","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183509733","pubTimestamp":1754483660,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Adaptive Biotechnologies Corp (ADPT) saw its stock surge 5.52% in pre-market trading on Wednesday, following the release of better-than-expected second-quarter results and an analyst upgrade.  The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"个股追踪|Adaptive Biotechnologies盘前大涨5.52%，Q2业绩强劲，目标价上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corp (ADPT) saw its stock surge 5.52% in pre-market trading on Wednesday, following the release of better-than-expected second-quarter results and an analyst upgrade.\nThe company reported a narrower loss of $0.17 per diluted share for Q2, compared to a loss of $0.31 a year earlier and beating analyst expectations of a $0.25 loss. Revenue for the quarter ended June 30 jumped to $58.9 million, significantly higher than the $43.2 million reported in the same period last year and surpassing the FactSet analyst consensus of $49.4 million.\nAdding to the positive sentiment, JP Morgan raised its price target for Adaptive Biotechnologies from $10 to $14, reflecting increased confidence in the company's future performance. The combination of strong financial results and the upgraded analyst outlook appears to be driving investor enthusiasm, resulting in the notable pre-market price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183509733?edition=fundamental&lang=en_us","isCrawlerRequest":true}